Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Weak
Earnings
Very Strong
Earnings
Neutral
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Strong
Website
Denali Therapeutics Inc.
Telephone
1.650.866.8547
Address
161 Oyster Point Boulevard, San Francisco, CA 94080
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 12.58 - 23.77
Trade Value (12mth)
US$7,353,002.00
1 week
-2.74%
1 month
-10.03%
YTD
11.31%
1 year
32.29%
All time high
93.94
EPS 3 yr Growth
14.30%
EBITDA Margin
0.00%
Operating Cashflow
-$413m
Free Cash Flow Return
-35.60%
ROIC
-44.20%
Interest Coverage
0.00
Quick Ratio
9.20
Shares Outstanding (Fully Diluted)
187m
HALO Sector
Healthcare
Next Company Report Date
01-Mar-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 08 May 26 | |
| 08 May 26 | |
| 08 May 26 | |
| 04 April 26 | |
| 31 March 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | -1.06 | -2.57 | -2.97 | | | | ||
EPS (Fully Diluted) | $ | | | | | -1.06 | -2.57 | -2.97 | | | | ||
Growth | % | | | | | 59.3 | -143.1 | -15.5 | | | | ||
PE | X | | | | | N/A | N/A | N/A | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
